Display options
Cite
Schallig HD, Tinto H, Sawa P, et al. Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Glob Health. 2017;2(3):e000371doi: 10.1136/bmjgh-2017-000371.
Schallig, H. D., Tinto, H., Sawa, P., Kaur, H., Duparc, S., Ishengoma, D. S., Magnussen, P., Alifrangis, M., & Sutherland, C. J. (2017). Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ global health, 2(3), e000371. https://doi.org/10.1136/bmjgh-2017-000371
Schallig, Henk Dfh, et al. "Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence." BMJ global health vol. 2,3 (2017): e000371. doi: https://doi.org/10.1136/bmjgh-2017-000371
Schallig HD, Tinto H, Sawa P, Kaur H, Duparc S, Ishengoma DS, Magnussen P, Alifrangis M, Sutherland CJ. Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Glob Health. 2017 Aug 30;2(3):e000371. doi: 10.1136/bmjgh-2017-000371. eCollection 2017. PMID: 29082016; PMCID: PMC5656137.
Copy Download .nbib Format: NLM
Share it on

BMJ Glob Health. 2017 Aug 30;2(3):e000371. doi: 10.1136/bmjgh-2017-000371. eCollection 2017.

Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.

BMJ global health

Henk Dfh Schallig, Halidou Tinto, Patrick Sawa, Harparkash Kaur, Stephan Duparc, Deus S Ishengoma, Pascal Magnussen, Michael Alifrangis, Colin J Sutherland

Affiliations

  1. Department of Medical Microbiology-Parasitology Unit, Academic Medical Centre, Amsterdam, The Netherlands.
  2. Institute for Health Sciences Research-Clinical Research Unit (IRSS-CRUN), Nanoro, Burkina Faso.
  3. International Centre for Insect Physiology and Ecology, Mbita Point, Kenya.
  4. Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  5. Immunology & Infection Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  6. Medicines for Malaria Venture, Geneva, Switzerland.
  7. National Institute for Medical Research, Tanga, Tanzania.
  8. Department of International Health, Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark.
  9. Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
  10. Public Health England Malaria Reference Laboratory, London School of Hygiene & Tropical Medicine, London, UK.

PMID: 29082016 PMCID: PMC5656137 DOI: 10.1136/bmjgh-2017-000371

Abstract

BACKGROUND: Management of uncomplicated

METHODS: We present an open-label, randomised three-arm clinical trial protocol in three African settings representative of varying malaria epidemiology to investigate whether prolonged ACT-based regimens using currently available formulations can eliminate potentially resistant parasites. The protocol investigates whether a sequential course of two licensed ACT in 1080 children aged 6-120 months exhibits superior efficacy against acute

DISCUSSION: This protocol addresses efficacy and safety of sequential ACT regimens in

Keywords: malaria; randomised control trial

Conflict of interest statement

Competing interests: None declared.

References

  1. N Engl J Med. 2014 Jul 31;371(5):411-23 - PubMed
  2. N Engl J Med. 2009 Jul 30;361(5):455-67 - PubMed
  3. Clin Pharmacokinet. 2010 Apr;49(4):239-58 - PubMed
  4. Antimicrob Agents Chemother. 2017 Feb 23;61(3):null - PubMed
  5. Antimicrob Agents Chemother. 2015 Oct;59(10):6419-27 - PubMed
  6. Antimicrob Agents Chemother. 2012 Apr;56(4):1997-2007 - PubMed
  7. PLoS One. 2011;6(11):e26005 - PubMed
  8. Mol Biochem Parasitol. 2004 Sep;137(1):35-41 - PubMed
  9. Nature. 2014 Jan 2;505(7481):50-5 - PubMed
  10. N Engl J Med. 2014 Jul 31;371(5):484-5 - PubMed
  11. Lancet Glob Health. 2017 Jan;5(1):e60-e68 - PubMed
  12. Malar J. 2008 Nov 18;7:237 - PubMed
  13. J Infect Dis. 2013 Dec 15;208(12):2017-24 - PubMed
  14. J Infect Dis. 2016 Apr 1;213(7):1134-42 - PubMed
  15. Antimicrob Agents Chemother. 2014 Aug;58(8):4583-92 - PubMed
  16. Lancet Infect Dis. 2015 Jun;15(6):621-3 - PubMed
  17. Malar J. 2017 Jan 13;16(1):27 - PubMed
  18. N Engl J Med. 2017 Mar 9;376(10 ):991-3 - PubMed
  19. Br J Clin Pharmacol. 1994 Mar;37(3):249-53 - PubMed
  20. Antimicrob Agents Chemother. 2015 Jan;59(1):734-7 - PubMed
  21. Clin Infect Dis. 2017 Jan 15;64(2):199-206 - PubMed
  22. Malar J. 2010 Nov 05;9:312 - PubMed
  23. Malar J. 2016 Jan 22;15:36 - PubMed
  24. J Infect Dis. 2015 Mar 1;211(5):680-8 - PubMed
  25. PLoS One. 2009 Nov 17;4(11):e7871 - PubMed
  26. J Postgrad Med. 2001 Jan-Mar;47(1):45-50 - PubMed
  27. Parasitology. 2011 Oct;138(12):1459-68 - PubMed
  28. PLoS One. 2013;8(3):e57689 - PubMed
  29. Malar J. 2015 Mar 29;14:135 - PubMed
  30. J Infect Dis. 2014 Dec 15;210(12):2001-8 - PubMed
  31. Malar J. 2014 May 31;13:207 - PubMed
  32. PLoS One. 2011;6(5):e19283 - PubMed
  33. Int J Parasitol. 2006 Apr;36(4):403-8 - PubMed

Publication Types